ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)

This study indicates that there are causal links between the gut microbiota and PCa. Feature genes may affect the occurrence of PCa by inhibiting the epithelial-mesenchymal transition, proliferation, migration, and invasion of cells.

Cyclin D1 can be used as a complementary marker in WNT-AG detection. ROR2 negativity may indicate G3 tumors, though further studies are warranted to confirm its prognostic value.

Conclusions. This study's findings validate OC as a novel lead entity for NEPC management by targeting the ROR2-ASCL1-SMYD2-EZH2-c-MET axis.

The computational results reveal that kinases like AKT1, ROR1, and ROR2, and non-kinase targets like UBC, RPS6, CDH1, AR, and SMAD3, are the most promising candidates. All screened compounds showed varying strong interacting profiles, with Ellagic Acid and Erioflorin standing out as potent candidates against critical targets in metastatic breast cancer.

CDH3 is a key marker and functional driver of basal-like prostate cancer. Therapeutic strategies leveraging CDH3, including ADCs and CAR T cells, demonstrate strong preclinical efficacy, supporting the development of CDH3-targeted treatments to overcome resistance in aggressive prostate cancer.

Intracellular calcium dysfunction was associated with key transcript dysregulation. We found an increased expression of CAMK2A and ROR2, suggesting a potential role for non-canonical Wnt pathway activation in CTNNB1 mutated tumors.

We confirm potent activity of ROR2-CAR T cells against ccRCC in vitro and in vivo. Treatment with ROR2-CAR T cells was well tolerated, without signs of on-target off-tumor toxicity in mice, supporting the role of ROR2 as an oncofetal antigen with utility for CAR T cell therapy.

The anti-tumorigenic effects of 24R,25(OH)2D3 in ER- UM-SCC-11A cells involve a membrane-receptor complex consisting of VDR, PDIA3, and ROR2 within caveolae to activate a yet-to-be-elucidated downstream signaling cascade. This work demonstrates a driving mechanism for the therapeutic agent 24R,25(OH)2D3 that may be used for laryngeal cancer patients.

Loss-of-function studies have demonstrated its essential role in driving tumor growth and metastasis, highlighting its oncogenic dependency and therapeutic potential. This review provides a comprehensive analysis of PKN3's structural motifs, multifunctional roles in physiology and disease, and emerging targeting strategies-including RNA interference (RNAi) and small-molecule inhibitors-to assess its translational potential in precision oncology.

Targeting the ROR2-YAP/TEAD axis presents a promising therapeutic approach to overcome trastuzumab resistance in HER2-positive cancers, offering a potential strategy for enhancing treatment efficacy and improving clinical outcomes.

This study identifies VIM3 expression in ABLs, distinct from VIMFL, suggesting its potential as a biomarker. Additionally, mitochondrial dysfunction may play a role in ABL tumorigenesis.

Understanding the dual roles of Wnt5a in PCa and bone metastasis is crucial for elucidating the underlying mechanisms of disease progression and identifying potential therapeutic targets. This review focuses on the current understanding of Wnt5a's role in PCa and bone metastasis, emphasizing its significance in tumor biology and clinical management.